White House Backtracks on Plan to Exert New Control Over N.I.H. Grants

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-23T19:58:59.341Z • Permanent link

The White House's plan to create a new commission with the power to veto federal research awards has hit a roadblock, with Democrats and Republicans in Congress opposing the proposal. According to sources, the commission would have been tasked with reviewing and approving research grants from the National Institutes of Health (NIH), with the power to reject or reduce funding. The proposal was met with fierce resistance from lawmakers, who argued that it would stifle scientific inquiry and undermine the independence of the NIH.

Led by White House Science Advisor Dr. Eric Lander, the proposal was seen as an attempt to exert greater control over the research agenda, with the goal of prioritizing high-priority research areas such as cancer and Alzheimer's disease. However, lawmakers from both parties were concerned that the commission would be used to politicize research funding, and would undermine the long-standing tradition of NIH independence. The opposition was led by Senator Patty Murray, a Democrat from Washington state, who stated that "the NIH should be free to make its own decisions about how to allocate funding, without interference from the White House.

The NIH has long been a bastion of scientific independence, and the proposal to create a new commission was seen as a threat to this tradition. In a statement, NIH Director Dr. Francis Collins said that "the NIH is committed to making its own decisions about how to allocate funding, and we will not be swayed by outside pressure." The opposition to the proposal was also fueled by concerns about the potential impact on the research community, with many scientists expressing fears that the commission would stifle innovation and limit the freedom to pursue research questions.

The White House's proposal to create a new commission with the power to veto federal research awards has significant implications for the research community, particularly in the Data Sources domain. Companies such as IBM, Google, and Microsoft, which rely heavily on NIH funding for research and development, are likely to be affected by any changes to the NIH's research agenda. Additionally, research communities in the life sciences, particularly in areas such as genomics and precision medicine, will be impacted by any changes to the NIH's funding priorities.

The potential impact on the markets is also significant, with many investors viewing the NIH as a key indicator of the health of the biotechnology sector. Any changes to the NIH's research agenda could have a ripple effect throughout the biotech industry, with investors and analysts closely watching for any signs of disruption. Furthermore, the proposal to create a new commission has also raised concerns about the potential for politicization of research funding, with many scientists and policymakers expressing concerns about the impact on the integrity of the research process.

The White House's proposal to create a new commission with the power to veto federal research awards is part of a broader pattern of attempts to exert greater control over the research agenda. In recent years, there have been several attempts to influence the NIH's research priorities, including the appointment of a new director who is seen as more aligned with the Trump administration's priorities. This has been met with resistance from the research community, who argue that the NIH should be free to make its own decisions about how to allocate funding.